CN110106161B - 青霉素酰化酶基因及其编码蛋白 - Google Patents

青霉素酰化酶基因及其编码蛋白 Download PDF

Info

Publication number
CN110106161B
CN110106161B CN201910385295.1A CN201910385295A CN110106161B CN 110106161 B CN110106161 B CN 110106161B CN 201910385295 A CN201910385295 A CN 201910385295A CN 110106161 B CN110106161 B CN 110106161B
Authority
CN
China
Prior art keywords
ala
leu
gly
arg
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910385295.1A
Other languages
English (en)
Other versions
CN110106161A (zh
Inventor
黄晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AFFILIATED STOMATOLOGICAL HOSPITAL FUJIAN MEDICAL UNIVERSITY
Original Assignee
AFFILIATED STOMATOLOGICAL HOSPITAL FUJIAN MEDICAL UNIVERSITY
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AFFILIATED STOMATOLOGICAL HOSPITAL FUJIAN MEDICAL UNIVERSITY filed Critical AFFILIATED STOMATOLOGICAL HOSPITAL FUJIAN MEDICAL UNIVERSITY
Priority to CN201910385295.1A priority Critical patent/CN110106161B/zh
Publication of CN110106161A publication Critical patent/CN110106161A/zh
Application granted granted Critical
Publication of CN110106161B publication Critical patent/CN110106161B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/78Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/84Penicillin amidase (3.5.1.11)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y305/00Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01011Penicillin amidase (3.5.1.11), i.e. penicillin-amidohydrolase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

本发明公开了青霉素酰化酶基因及其编码蛋白,所述青霉素酰化酶基因的核酸序列如SEQ ID NO.1所示,该青霉素酰化酶基因的编码蛋白具有如SEQ ID NO.2所示的氨基酸序列。本发明的青霉素酰化酶在工业实际应用中具有良好的稳定性和活性。

Description

青霉素酰化酶基因及其编码蛋白
技术领域
本发明涉及生物基因领域,具体涉及青霉素酰化酶基因及其编码蛋白。
背景技术
青霉素和头孢霉素同属于β-内酰胺抗生素,被认为是最有发展前景的抗生素。在医药领域,β-内酰胺抗生素的应用非常广泛,工业产量很大,创造了大量的经济价值。但是由于抗生素耐药性问题的存在,需要不断地改进该类型抗生素的化学结构,以提高其对耐药菌的敏感性。最有效的一个做法,就是改变该类型抗生素的侧链基团,进而改变其抗菌特性。而侧链基团的修饰,常用的方法有化学法和酶法。化学法的环境污染严重,毒性大,已经逐渐被淘汰。而酶法由于反应效率高,环境友好,备受推崇。
青霉素酰化酶,又称为青霉素酰胺酶或青霉素氨基水解酶。该酶可以催化青霉素或者头孢霉素水解生成6-氨基青霉烷酸(6-APA)或者7-氨基头孢霉烷酸 (7-ACA),也可以催化青霉素酰基化反应,进而由6-ACA或者7-ACA合成新型的抗生素。由某些微生物产生的该酶,已大规模应用于工业生产β-内酰胺类抗生素的关键中间体和半合成β-内酰胺类抗生素。但是,不同微生物来源的青霉素酰化酶,在催化特性、效率、稳定性等等各方面,具有不同的特点,因此适用于不同的应用场景。
发明内容
本发明的目的在于提供青霉素酰化酶基因及其编码蛋白。
本发明所提供的青霉素酰化酶基因,其核酸序列如SEQ ID NO.1所示。
本发明还提供了上述青霉素酰化酶基因所编码的蛋白,所述蛋白的氨基酸序列如SEQ ID NO.2所示。
本发明所述的青霉素酰化酶基因,是从10份不同来源的牙面上的牙菌斑混合物中,通过宏基因组学技术,使用试剂盒提取宏基因组DNA,并直接对提取好的DNA进行PCR扩增得到。
本发明青霉素酰化酶基因编码的青霉素酰化酶能够在45℃环境中维持较高的活性,在日常储存和运输中,表现出良好的稳定性,满足工业实际应用的需求。
附图说明
图1为实施例1步骤1中PCR产物的电泳图谱。
图2为实施例1步骤4 中重组质粒图谱。
具体实施方式
以下结合附图和实施例对本发明做进一步说明。以下未注明具体条件的实验方法,按照本领域常规实验条件或者制造厂商所建议的条件。
本发明所述青霉素酰化酶基因的核酸序列如SEQ ID NO.1所示。
上述青霉素酰化酶基因的编码蛋白的氨基酸序列如SEQ ID NO.2所示。
本申请所述的青霉素酰化酶基因来源,是从10份不同来源的牙面上的牙菌斑混合物中,通过宏基因组学技术,使用试剂盒(Mobio牌,
Figure BDA0002054640940000022
DNA Isolation Kit,14900-50-NF,USA)提取宏基因组DNA,并直接对提取好的DNA 进行PCR扩增得到。
实施例1
通过分子克隆技术,构建青霉素酰化酶基因的蛋白表达载体
1、直接对提取好的宏基因组DNA做PCR扩增(50μl体系)
上游引物GTTAGCAGCCGGATCATGGAGACGACGATGGCGCGA
下游引物ATATGCTCGAGGATCCTACCGTGAAAACAAGAGCGTATGTTGGGC
PCR体系:
Figure BDA0002054640940000021
PCR程序:
95℃预变性2min,(94℃变性30s,64℃退火30s;72℃延伸150s)X 35cycles,最后72℃延伸10min。
PCR产物采用琼脂糖凝胶电泳进行鉴定,结果如图1所示,泳道M是 Takara 250bpDNA ladder marker,泳道1是目的基因。
本步骤所得PCR产物使用sanger法测序(ABI 3730xl测序仪双向测序,测序引物为上述“上游引物”和“下游引物”,由广州英骏生物公司完成),得到本发明所述青霉素酰化酶基因的核酸序列,如SEQ ID NO.1所示。
根据三联密码子,将该核酸序列翻译成蛋白序列。该蛋白序列进行NCBI Blast比对搜索,得到的具有最高同源性的序列是Genbank WP_047822973.1记录下的蛋白序列,具有82.71%的氨基酸同源性。
2、胶回收
使用Omega公司胶回收试剂盒,货号D2500-01,对步骤1的PCR产物中的目的条带,进行割胶回收。将胶回收后的该基因的PCR产物的浓度调整为50ng/ μl,作为后续infusion连接反应的底物,用于连接到表达载体上。
3、线性化表达质粒的准备构建蛋白表达载体:
质粒载体选择pET15b,先对载体酶切
Figure BDA0002054640940000031
在37℃下保温30min
酶切产物采用琼脂糖凝胶电泳鉴定,用上述的omega试剂盒回收酶切产物条带。胶回收产物浓度为27ng/μl。以上即为制备好的线性化的质粒载体,用于后续的In fusion反应。
4、In-Fusion连接反应
将纯化好的PCR产物与质粒表达载体相互连接,构建表达载体。
Figure BDA0002054640940000032
50℃保温15min,然后置于冰上
重组质粒图谱如图2所示。
5、转化
取In-Fusion连接反应获得的连接产物10μl,加入到大肠杆菌NEB-10beta感受态细胞中,混匀冰浴30min,42℃热激45s,冰浴2min,涂LB平板(带有氨苄青霉素抗性),将平板置于培养箱中培养,平板上形成单克隆菌落。
6、验证单克隆
挑取单克隆菌落至10μl无菌水中,吹打混匀,取1μl作模板(10个,编号 1~10)进行菌落PCR,验证目的基因是否连接到质粒载体上。
PCR体系:
Figure BDA0002054640940000041
对照:
Figure BDA0002054640940000042
PCR程序:94℃预变性10min,(94℃变性30s;55℃退火30s;72℃延伸2.5min) ×35cycles,最后72℃延伸10min。PCR产物电泳检测,通过目的条带的有无和大小,判断目的基因是否成功连接于载体。
7、测序验证与表达菌株的构建
取有目的条带的样品菌,接种到带有氨苄青霉素抗性的液体LB培养基中,培养过夜,菌液送至广州英骏生物公司测序验证,使用T7上游和下游通用测序引物进行测序,结果显示序列正确。然后提取该样品的质粒DNA,将质粒DNA 转化到大肠杆菌ER2566细胞(蛋白表达的宿主菌)内,将ER2566培养过夜。
实施例2
蛋白表达部分:
1、诱导表达
1)取实施例1步骤7中过夜培养的菌液300μL,加入到30mL LB中,再加氨苄青霉素,37℃,200rpm培养。
2)大约2h后测OD,当OD值达到0.5(0.3~0.5)时,加入IPTG,终浓度 0.1mM,然后20℃,200rpm培养12h。
2、酶法裂解细胞(30mL菌液)
1)4000g,10min离心收集菌体,去上清,用高纯水洗一次(高纯水重悬沉淀再离心去上清)。
2)每30mL菌液对应的沉淀重悬于1.2mL cell lysis buffer(pH 8.5),buffer 需要确保添加有PMSF。
3)加入溶菌酶粉末至终浓度1mg/mL,混匀,冰浴30min。
4)将离心管转移到摇床,旋紧盖子,倾斜45度放置,230rpm,25℃,震荡10min。
5)加入Triton X-100 12μL(终浓度为1%),DNA酶0.5μL和RNA酶1μL (终浓度均为5μg/mL),置于摇床上,230rpm,25℃,震荡15min。
6)4℃,12000g离心15min,上清为可溶蛋白组分,沉淀为细胞碎片和不溶蛋白组分。上清液用于后续实验。
上清液中基因工程重组表达的青霉素酰化酶,其蛋白序列如SEQ ID NO.2 所示。
3、活性检测
根据文献(邵威平,吴卓颖,张永玲,杨富民,田常庆.产青霉素G酰化酶工程菌的构建[J].甘肃农业大学学报,2016,51(01):132-137)的方法,测定上述上清液中青霉素酰化酶的活性,可达56U/mL。
将Genbank记录的WP_047822973.1的蛋白序列,也用上述方法进行蛋白表达。将本发明的青霉素酰化酶,与WP_047822973.1的酶,各取100U总量,平行实验操作如下:用10KDa的超滤膜过滤截留蛋白质,用等体积的pH 7.0的纯水重悬膜上截留的蛋白。45℃保温72小时。在保温前后,各取样测定酶活性。本发明的酶蛋白,在72h后仍保留有84%的酶活性。WP_047822973.1序列来源的酶蛋白,仅保留有67%的酶活性。以上结果表明,本发明的酶蛋白,与 WP_047822973.1相比,具有更好的稳定性和活性。
日常工业领域使用青霉素酰化酶时,一般需要物流运输和储存,将酶制剂从酶工厂运送到抗生素厂家。而有些情况下,由于气温高、运输时间长、仓库储存时间久等不利因素的影响,容易导致酶活性降低,从而造成经济损失。上述酶稳定性测定方法,模拟了酶产品日常储存和运输的情况,说明本发明的青霉素酰化酶,在工业实际应用中,具有更佳的稳定性。
序列表
<110> 福建医科大学附属口腔医院
<120> 青霉素酰化酶基因及其编码蛋白
<130> 2019
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2421
<212> DNA
<213> 人工序列(Artificial sequence )
<400> 1
atggagacga cgatggcgcg acgggcatgg ctgatctggg gacggcgtac gctgctgctg 60
atcctggccc tggtgttgct ggccgtgctg ggtgtctggc tgttcctgcg tgccagcctg 120
gcgcagctcg acggcaaggt cgtgtcgccg cagctgagcg gttccgtgac cgtcacgcgc 180
gacgccaacg gcgtgccgac gatcagcggc gccgaccgga tcgacctggc ctatgccgcc 240
ggctacgtgc acgcccagga gcgcttcttc cagatggacc tgctgcgccg cagcgccgcc 300
ggcgagctgg ccgagctgtt cgggccgaag gcgctgccgc tcgaccgcgc gcatcgcctg 360
caccgcttcc gcgcccgtgc gctcgaggcg ctggcgcgcc tgagcccgga gcagcgccgc 420
ttcgtcgagc gctatgccgc cggcgtcaac gacggcctga atgcgctcgg cgcacggccc 480
ttcgaatatg cgctgaccgg cgccagaccg cggccctgga ccgcagccga ttcgctgctg 540
acggtgtggg ccatgtacat cgatttgcag ggcaaccagg aggcacgcga cctggcgcgc 600
ggctggctgg caagccacac cacgcctgag cagcgcgcct tcctgatgcc cgaagccagc 660
cgctgggatg cgccgctcga cgcccccggc gtggatgtgg ccgcggcggc cgtgcccgcc 720
gcgccgcccg catggtggca ccgcaaggat gcgctgccgg cgcgccaggt ggccggcatc 780
gatttcaccg acgcggtcgg cagcaacaac tatgcggtgg ccggcacgcg caccgccagc 840
ggggcggcga tcgtctcgga cgacatgcac ctcggcctgc agttgccgaa tacctggtac 900
cggctggcgc tgcgctttcc cgacgcgcaa ggcgggcagc ggcgcgtggt cggcgtaagc 960
ctgccgggcg cgccgccgct ggtgatcgtc ggcagcaatg gccatgtggc ctgggccttc 1020
accaacagct atgccgacac gctcgacctg gtccgcctgg gcaccgaccg cgcacgcgcc 1080
gggcaggtac ggacgccggc cggctgggag acgccgctgg aaaaggtcga gacgattttg 1140
gtgaaaggcc agccggccga acgcgtgctc gtgcgcgaga ccagcctggg accgatccgc 1200
gaagccggcg gcgaactcta tgcgatccac tggatcgcgc atgcgccgca ggcggtcaac 1260
ctcgaacacc tgcgcatgga aaccgcgacc acgctggacg acgcgatggc ggtggcggcc 1320
gtcgacggta tcccggcgca gaacatcctg atcggcgacg agcgcggcaa tatcggctgg 1380
accgtcgccg gcatcctgcc gcaccgtccc gcggccggcc gcgggctggc cgtgtccttc 1440
ccgctggacg cgagcggcag cgttccggcc tgggacggcg tgctggcgcc ggccgactat 1500
ccgcatgtgg tgaatccgcc gggtgggcaa ctggtgaccg ccaacaaccg ccagctggcc 1560
ggaccgaacg cgcaagtgct cggcgacggc ggcttcgacc tcggcgcgcg tgcgcgccag 1620
ctgggcgagg gcgtgcgcag cctgggcgac aagaccgacg tgccggccac cttccgcgcg 1680
gcgctcgacg atcgcgcgct gttcgtgcag gagtggcgcg agcgcgccct ggcggcgctc 1740
gacgacgcgg ccgtcgccgg ccatccggag cgtgcggagt tccgccgcct gctgaaggaa 1800
agctgggatg gccatgccag caccggctcg gtcggctacc gcctggcgca gcagttccgc 1860
tggtcgctgt acgagctggt gttcgccggc gcgaatgccg agatggccag gctcgatccg 1920
aaggccagca tgcagagcgc cagctcgcgc tggtcggcgg tgctggcgcg cctgctggac 1980
gagcgcccgg cggcctggct gccgtccggc tatgccagct ggcaggacct gcagctggcc 2040
gcggtcgacc gcacgatccg cgatgtcacc aaggacggca cgccgctggc ccgggccacc 2100
tggggcgcgc gcaacacggc ggcgatcgcg catccgatca gcatggcgct gcctttcctg 2160
aagcgttggc tgggcgcgcc gcccgaccag ctgccgggcg acgccaacat gccgcgcgtg 2220
gcagggccga agttcggcca gtcggagcgc ctgacggtgt cgccggggcg ggaagaagag 2280
gggctgttcg acatgcccgg cgggcagagc gggcatccgc tgtcgccctg gttcctgggc 2340
gggcatgcgg actgggtgcg cgggaagccg accccgctgc tgccggggcc ggcccaacat 2400
acgctcttgt tttcacggta g 2421
<210> 2
<211> 806
<212> PRT
<213> 人工序列(Artificial sequence )
<400> 2
Met Glu Thr Thr Met Ala Arg Arg Ala Trp Leu Ile Trp Gly Arg Arg
1 5 10 15
Thr Leu Leu Leu Ile Leu Ala Leu Val Leu Leu Ala Val Leu Gly Val
20 25 30
Trp Leu Phe Leu Arg Ala Ser Leu Ala Gln Leu Asp Gly Lys Val Val
35 40 45
Ser Pro Gln Leu Ser Gly Ser Val Thr Val Thr Arg Asp Ala Asn Gly
50 55 60
Val Pro Thr Ile Ser Gly Ala Asp Arg Ile Asp Leu Ala Tyr Ala Ala
65 70 75 80
Gly Tyr Val His Ala Gln Glu Arg Phe Phe Gln Met Asp Leu Leu Arg
85 90 95
Arg Ser Ala Ala Gly Glu Leu Ala Glu Leu Phe Gly Pro Lys Ala Leu
100 105 110
Pro Leu Asp Arg Ala His Arg Leu His Arg Phe Arg Ala Arg Ala Leu
115 120 125
Glu Ala Leu Ala Arg Leu Ser Pro Glu Gln Arg Arg Phe Val Glu Arg
130 135 140
Tyr Ala Ala Gly Val Asn Asp Gly Leu Asn Ala Leu Gly Ala Arg Pro
145 150 155 160
Phe Glu Tyr Ala Leu Thr Gly Ala Arg Pro Arg Pro Trp Thr Ala Ala
165 170 175
Asp Ser Leu Leu Thr Val Trp Ala Met Tyr Ile Asp Leu Gln Gly Asn
180 185 190
Gln Glu Ala Arg Asp Leu Ala Arg Gly Trp Leu Ala Ser His Thr Thr
195 200 205
Pro Glu Gln Arg Ala Phe Leu Met Pro Glu Ala Ser Arg Trp Asp Ala
210 215 220
Pro Leu Asp Ala Pro Gly Val Asp Val Ala Ala Ala Ala Val Pro Ala
225 230 235 240
Ala Pro Pro Ala Trp Trp His Arg Lys Asp Ala Leu Pro Ala Arg Gln
245 250 255
Val Ala Gly Ile Asp Phe Thr Asp Ala Val Gly Ser Asn Asn Tyr Ala
260 265 270
Val Ala Gly Thr Arg Thr Ala Ser Gly Ala Ala Ile Val Ser Asp Asp
275 280 285
Met His Leu Gly Leu Gln Leu Pro Asn Thr Trp Tyr Arg Leu Ala Leu
290 295 300
Arg Phe Pro Asp Ala Gln Gly Gly Gln Arg Arg Val Val Gly Val Ser
305 310 315 320
Leu Pro Gly Ala Pro Pro Leu Val Ile Val Gly Ser Asn Gly His Val
325 330 335
Ala Trp Ala Phe Thr Asn Ser Tyr Ala Asp Thr Leu Asp Leu Val Arg
340 345 350
Leu Gly Thr Asp Arg Ala Arg Ala Gly Gln Val Arg Thr Pro Ala Gly
355 360 365
Trp Glu Thr Pro Leu Glu Lys Val Glu Thr Ile Leu Val Lys Gly Gln
370 375 380
Pro Ala Glu Arg Val Leu Val Arg Glu Thr Ser Leu Gly Pro Ile Arg
385 390 395 400
Glu Ala Gly Gly Glu Leu Tyr Ala Ile His Trp Ile Ala His Ala Pro
405 410 415
Gln Ala Val Asn Leu Glu His Leu Arg Met Glu Thr Ala Thr Thr Leu
420 425 430
Asp Asp Ala Met Ala Val Ala Ala Val Asp Gly Ile Pro Ala Gln Asn
435 440 445
Ile Leu Ile Gly Asp Glu Arg Gly Asn Ile Gly Trp Thr Val Ala Gly
450 455 460
Ile Leu Pro His Arg Pro Ala Ala Gly Arg Gly Leu Ala Val Ser Phe
465 470 475 480
Pro Leu Asp Ala Ser Gly Ser Val Pro Ala Trp Asp Gly Val Leu Ala
485 490 495
Pro Ala Asp Tyr Pro His Val Val Asn Pro Pro Gly Gly Gln Leu Val
500 505 510
Thr Ala Asn Asn Arg Gln Leu Ala Gly Pro Asn Ala Gln Val Leu Gly
515 520 525
Asp Gly Gly Phe Asp Leu Gly Ala Arg Ala Arg Gln Leu Gly Glu Gly
530 535 540
Val Arg Ser Leu Gly Asp Lys Thr Asp Val Pro Ala Thr Phe Arg Ala
545 550 555 560
Ala Leu Asp Asp Arg Ala Leu Phe Val Gln Glu Trp Arg Glu Arg Ala
565 570 575
Leu Ala Ala Leu Asp Asp Ala Ala Val Ala Gly His Pro Glu Arg Ala
580 585 590
Glu Phe Arg Arg Leu Leu Lys Glu Ser Trp Asp Gly His Ala Ser Thr
595 600 605
Gly Ser Val Gly Tyr Arg Leu Ala Gln Gln Phe Arg Trp Ser Leu Tyr
610 615 620
Glu Leu Val Phe Ala Gly Ala Asn Ala Glu Met Ala Arg Leu Asp Pro
625 630 635 640
Lys Ala Ser Met Gln Ser Ala Ser Ser Arg Trp Ser Ala Val Leu Ala
645 650 655
Arg Leu Leu Asp Glu Arg Pro Ala Ala Trp Leu Pro Ser Gly Tyr Ala
660 665 670
Ser Trp Gln Asp Leu Gln Leu Ala Ala Val Asp Arg Thr Ile Arg Asp
675 680 685
Val Thr Lys Asp Gly Thr Pro Leu Ala Arg Ala Thr Trp Gly Ala Arg
690 695 700
Asn Thr Ala Ala Ile Ala His Pro Ile Ser Met Ala Leu Pro Phe Leu
705 710 715 720
Lys Arg Trp Leu Gly Ala Pro Pro Asp Gln Leu Pro Gly Asp Ala Asn
725 730 735
Met Pro Arg Val Ala Gly Pro Lys Phe Gly Gln Ser Glu Arg Leu Thr
740 745 750
Val Ser Pro Gly Arg Glu Glu Glu Gly Leu Phe Asp Met Pro Gly Gly
755 760 765
Gln Ser Gly His Pro Leu Ser Pro Trp Phe Leu Gly Gly His Ala Asp
770 775 780
Trp Val Arg Gly Lys Pro Thr Pro Leu Leu Pro Gly Pro Ala Gln His
785 790 795 800
Thr Leu Leu Phe Ser Arg
805

Claims (2)

1.青霉素酰化酶基因,其特征在于:所述基因的核酸序列如SEQ ID NO.1所示。
2.如权利要求1所述的青霉素酰化酶基因所编码的蛋白,其特征在于:所述蛋白的氨基酸序列如SEQ ID NO.2所示。
CN201910385295.1A 2019-05-09 2019-05-09 青霉素酰化酶基因及其编码蛋白 Active CN110106161B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910385295.1A CN110106161B (zh) 2019-05-09 2019-05-09 青霉素酰化酶基因及其编码蛋白

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910385295.1A CN110106161B (zh) 2019-05-09 2019-05-09 青霉素酰化酶基因及其编码蛋白

Publications (2)

Publication Number Publication Date
CN110106161A CN110106161A (zh) 2019-08-09
CN110106161B true CN110106161B (zh) 2022-03-22

Family

ID=67489121

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910385295.1A Active CN110106161B (zh) 2019-05-09 2019-05-09 青霉素酰化酶基因及其编码蛋白

Country Status (1)

Country Link
CN (1) CN110106161B (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008093351A1 (en) * 2007-01-31 2008-08-07 Fermenta Biotech Limited Dna sequence encoding penicillin acylase, novel recombinant dna constructs and recombinant microorganisms carrying this sequence
CN104789510A (zh) * 2015-05-06 2015-07-22 南京工业大学 一种青霉素酰化酶、编码基因、产生菌株及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008093351A1 (en) * 2007-01-31 2008-08-07 Fermenta Biotech Limited Dna sequence encoding penicillin acylase, novel recombinant dna constructs and recombinant microorganisms carrying this sequence
CN104789510A (zh) * 2015-05-06 2015-07-22 南京工业大学 一种青霉素酰化酶、编码基因、产生菌株及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cloning, overexpression, and characterization of a novel thermostable penicillin g acylase from Achromobacter xylosoxidans: Probing the molecular basis for its high thermostability;Cai, G等;《APPLIED AND ENVIRONMENTAL MICROBIOLOGY》;20140501;第70卷(第5期);第2764-2770页,参见全文 *
Expression and characterization of a thermostable penicillin G acylase from an environmental metagenomic library;Zhang, Q等;《BIOTECHNOLOGY LETTERS》;20131211;第36卷(第3期);第617-625页,参见全文 *
产青霉素G酰化酶工程菌的构建;邵威平等;《甘肃农业大学学报》;20160215;第51卷(第01期);第132-137页,参见全文 *
成都平原蜘蛛内生菌宏基因组文库构建及新型青霉素酰化酶的初步筛选;谢超颖等;《基因组学与应用生物学》;20170125;第36卷(第01期);第259-265页,参见全文 *

Also Published As

Publication number Publication date
CN110106161A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
Zhu et al. A simple and effective strategy for solving the problem of inclusion bodies in recombinant protein technology: His-tag deletions enhance soluble expression
CN111808837A (zh) 一种金黄色葡萄球菌噬菌体裂解酶及其制备方法和应用
CN113151270A (zh) 一种高效表达碱性蛋白酶的启动子及其应用
US11807883B2 (en) Polypeptide tag, highly soluble recombinant nitrilase and application thereof in synthesis of pharmaceutical chemicals
CN115029333B (zh) 一种核酸内切酶及其纯化方法和应用
CN110106161B (zh) 青霉素酰化酶基因及其编码蛋白
CN110078791B (zh) 一种基于氨基酸特异性识别实现蛋白质交联的方法
CN110283797B (zh) 一种酪氨酸酶及其基因、工程菌和制备方法
Suzuki et al. Gene cloning, overproduction, and characterization of thermolabile alkaline phosphatase from a psychrotrophic bacterium
US8017356B2 (en) Endoribonuclease
CN112481286B (zh) 提高重组牛奶蛋白异源表达效率的氨基酸序列
CN118139979A (zh) 具有hepn结构域的酶
CN115948363A (zh) Tn5转座酶突变体及其制备方法和应用
CN112592929A (zh) 一种卤化酶重组表达载体制备方法及其应用
CN107619832B (zh) 一种氯代硝基苯酚类化合物氧化还原酶基因簇cnpAB及其应用
CN110698554A (zh) 东亚飞蝗fkbp52蛋白及其编码基因和应用
CN110066814B (zh) β-D-葡萄糖苷酶基因及其编码蛋白
EP1921138A1 (en) Novel endoribonuclease
AU2021100409A4 (en) Recombinant low-temperature catalase, recombinant vector and engineered strain thereof
CN114164223B (zh) 一种南极土壤来源的酯酶及其编码基因与应用
CN114561386B (zh) 一种具有分子内伴侣特性的基因元件及其应用
KR102667373B1 (ko) 탄수화물결합모듈66과 레반을 이용한 재조합 단백질의 가용성 발현 및 정제를 위한 신규 융합 태그 시스템 및 이의 활용
CN113151227B (zh) 一种蛋白酶基因及其异源表达
CN116875582B (zh) 一种核苷水解酶突变体、基因、表达载体、细胞及其应用
CN107857801B (zh) 一种可用于提高分泌效率的信号肽及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant